3 results
Approved WMOCompleted
Primary objective* To demonstrate the effect of ACT-293987 on time to first morbidity and mortality (MM) event in patients with pulmonary arterial hypertension (PAH).Secondary objective * To evaluate the effect of ACT-293987 on exercise capacity and…
Not approvedWill not start
The aim of the study is to show that a therapy based on a thrice weekly administration (i.e. at each HD session) of vitamin K1 for a period of 18 months attenuates the progression of coronary artery and thoracic aortic calcifications compared to…
Approved WMOCompleted
To assess the long-term safety and tolerability of selexipag (ACT-293987) in patients with pulmonary arterial hypertension (PAH).